Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Replacement Statement re US Subsidiary Update

30 Oct 2025 11:30

RNS Number : 5342F
Belluscura PLC
30 October 2025
 

The following amendment has been made to the "Statement re US Subsidiary Chapter 7 Update" announcement released on 30/10/25 at 10.38 under RNS No 5186F.

 

The announcement was issued today, 30 October 2025, and confirms that on 29 October 2025 Belluscura LLC filed for Chapter 7 Bankruptcy under the U.S Bankruptcy Code.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

 

 

30 October 2025

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura LLC

 

Further to the notification of 28 October 2025, the Company confirms that on 29 October 2025 Belluscura LLC filed for Chapter 7 Bankruptcy under the U.S Bankruptcy Code.

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

 

SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

Dowgate Capital Limited

Joint Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Daniel Ingram (Corporate Finance)

Allenby Capital Ltd

Joint Broker

Tel: +44 (0)20 3328 5656

 

Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

 

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREAFEEDASSFFA
Date   Source Headline
12th Oct 202312:42 pmBUSForm 8.3 - Belluscura plc
12th Oct 20239:55 amRNSForm 8.3 - BELLUSCURA PLC
11th Oct 20234:20 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20235:10 pmRNSForm 8.3 - TMT ACQUISITION PLC
10th Oct 20235:09 pmRNSForm 8.3 - [BELLUSCURA PLC]
10th Oct 20234:40 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20234:21 pmRNSForm 8.3 - BELLUSCURA PLC
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement regarding possible offer
3rd Oct 20231:30 pmRNSStatement re Possible Offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.